Role of extended release quetiapine in the management of bipolar disorders

Rayan K Al Jurdi1,2, Lena A Dixit1, Martha Sajatovic3 1Baylor College of Medicine, Department of Psychiatry, Houston, Texas, USA; 2South Central Mental Illness Research and Clinical Core, Department of Veterans Affairs, Houston, Texas; 3Department of Psychiatry, Case Western Reserve University Schoo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rayan K Al Jurdi, Lena A Dixit, Martha Sajatovic
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/20da0ae74c044a0cb6f4ccaa588c667c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:20da0ae74c044a0cb6f4ccaa588c667c
record_format	dspace
spelling	oai:doaj.org-article:20da0ae74c044a0cb6f4ccaa588c667c2021-12-02T08:24:01ZRole of extended release quetiapine in the management of bipolar disorders1176-63281178-2021https://doaj.org/article/20da0ae74c044a0cb6f4ccaa588c667c2010-02-01T00:00:00Zhttp://www.dovepress.com/role-of-extended-release-quetiapine-in-the-management-of-bipolar-disor-a3969https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Rayan K Al Jurdi1,2, Lena A Dixit1, Martha Sajatovic3 1Baylor College of Medicine, Department of Psychiatry, Houston, Texas, USA; 2South Central Mental Illness Research and Clinical Core, Department of Veterans Affairs, Houston, Texas; 3Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USAAbstract: Atypical antipsychotics have become a widely utilized component of the bipolar disorder treatment armamentarium, with approximately 45% of bipolar patients prescribed atypicals. Over the last decade all atypical drugs except for clozapine have received a Food and Drug Administration (FDA) bipolar indication. In October 2008, the FDA approved quetiapine XR monotherapy for the treatment of acute depressive episodes of bipolar disorder and acute manic or mixed episodes in bipolar I disorder based on two placebo-control trials. Quetiapine was also approved as adjunct therapy with lithium and divalproex for the treatment of acute manic or mixed episodes as well as maintenance of bipolar I disorder. In contrast to immediate release quetiapine which may require a twice-daily regimen, the XR formulation is intended for once-daily administration. This drug profile of quetiapine XR will address chemistry, pharmacodynamics, pharmacokinetics, metabolism, safety and tolerability and clinical trials in bipolar disorder.Keywords: quetiapine XR, bipolar disorder Rayan K Al JurdiLena A DixitMartha SajatovicDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 29-35 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Rayan K Al Jurdi Lena A Dixit Martha Sajatovic Role of extended release quetiapine in the management of bipolar disorders
description	Rayan K Al Jurdi1,2, Lena A Dixit1, Martha Sajatovic3 1Baylor College of Medicine, Department of Psychiatry, Houston, Texas, USA; 2South Central Mental Illness Research and Clinical Core, Department of Veterans Affairs, Houston, Texas; 3Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USAAbstract: Atypical antipsychotics have become a widely utilized component of the bipolar disorder treatment armamentarium, with approximately 45% of bipolar patients prescribed atypicals. Over the last decade all atypical drugs except for clozapine have received a Food and Drug Administration (FDA) bipolar indication. In October 2008, the FDA approved quetiapine XR monotherapy for the treatment of acute depressive episodes of bipolar disorder and acute manic or mixed episodes in bipolar I disorder based on two placebo-control trials. Quetiapine was also approved as adjunct therapy with lithium and divalproex for the treatment of acute manic or mixed episodes as well as maintenance of bipolar I disorder. In contrast to immediate release quetiapine which may require a twice-daily regimen, the XR formulation is intended for once-daily administration. This drug profile of quetiapine XR will address chemistry, pharmacodynamics, pharmacokinetics, metabolism, safety and tolerability and clinical trials in bipolar disorder.Keywords: quetiapine XR, bipolar disorder
format	article
author	Rayan K Al Jurdi Lena A Dixit Martha Sajatovic
author_facet	Rayan K Al Jurdi Lena A Dixit Martha Sajatovic
author_sort	Rayan K Al Jurdi
title	Role of extended release quetiapine in the management of bipolar disorders
title_short	Role of extended release quetiapine in the management of bipolar disorders
title_full	Role of extended release quetiapine in the management of bipolar disorders
title_fullStr	Role of extended release quetiapine in the management of bipolar disorders
title_full_unstemmed	Role of extended release quetiapine in the management of bipolar disorders
title_sort	role of extended release quetiapine in the management of bipolar disorders
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/20da0ae74c044a0cb6f4ccaa588c667c
work_keys_str_mv	AT rayankaljurdi roleofextendedreleasequetiapineinthemanagementofbipolardisorders AT lenaadixit roleofextendedreleasequetiapineinthemanagementofbipolardisorders AT marthasajatovic roleofextendedreleasequetiapineinthemanagementofbipolardisorders
_version_	1718398532932599808

Role of extended release quetiapine in the management of bipolar disorders

Ejemplares similares